Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapy.
Med Mycol
; 56(6): 782-786, 2018 Aug 01.
Article
em En
| MEDLINE
| ID: mdl-29228331
We performed a retrospective study involving 21 patients with chronic disseminate candidiasis (CDC) and 38 patients with candidemia. Neutropenia of >2 weeks' duration was more common in those with CDC (71%) than in those with candidemia (26%, P < .001), and the azole-resistant rate in patients with CDC (5%) was lower than that in those with candidemia (29%, P = .03). Of the 21 patients with CDC, five (24%) needed adjuvant corticosteroid therapy due to persistent debilitating fever (median, 19 days). Rapid defervescence (median, 5 days) occurred after adjuvant corticosteroid therapy. However, there were no significant differences in 90-day mortality between CDC patients with and without corticosteroid therapy. Further prospective data are needed to define the role of steroids in this setting.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Candidíase
/
Corticosteroides
/
Antifúngicos
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article